LOGIN  |  REGISTER
Amneal Pharmaceuticals
Amneal Pharmaceuticals

Solventum to Report Fourth Quarter and Full Year Fiscal 2024 Earnings on February 27, 2025

January 30, 2025 | Last Trade: US$65.67 0.26 -0.39
  • Company to host an Investor Day in March 2025

ST. PAUL, Minn., Jan. 30, 2025 /PRNewswire/ -- Solventum (NYSE: SOLV) will release its fourth quarter fiscal year 2024 financial results on Thursday, February 27, 2025, after the U.S. financial markets close. Following the release, Solventum management will host a webcast to discuss the results and fiscal year 2025 outlook. Other forward-looking and material information may also be discussed during the webcast.

Earnings webcast details:

Date:

Thursday, February 27, 2025

Time:

3:30 p.m. CST / 4:30 p.m. EST

Location:

https://investors.solventum.com

U.S. dial-in

+1 (800) 715-9871

International dial-in:

+1 (646) 307-1963

Conference ID:

6342275

A replay of the webcast, the earnings press release, presentation slides, and supplemental financial disclosures, will be available on the Investor Relations section of Solventum's website.

Other upcoming Investor Events:

2025 Investor Day  

Mid-March (location: NYC)

Additional details to follow

Solventum plans to host an Investor Day in March in New York City to introduce its strategy to accelerate growth and its long-range financial plan. More details and registration information will be shared soon.

About Solventum

At Solventum, we enable better, smarter, safer healthcare to improve lives. As a new company with a long legacy of creating breakthrough solutions for our customers' toughest challenges, we pioneer game-changing innovations at the intersection of health, material and data science that change patients' lives for the better — while empowering healthcare professionals to perform at their best. See how at Solventum.com.

Stock Quote

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page